The research team set out to answer a deceptively simple question: can the immune cells already present inside a bladder tumor, before any BCG is given, reveal how a patient will fare after therapy? Current clinical practice relies heavily on clinicopathological features such as tumor grade, stage, size and the number of tumors to estimate recurrence risk, most famously through risk tables developed by the European Organization for Research and Treatment of Cancer (EORTC) and the Club Urologico Español de Tratamiento Oncológico (CUETO). These tools are useful, but they capture nothing about the biology of the immune response that BCG is supposed to provoke. The Chinese team suspected that the missing ingredient lay in the tumor immune microenvironment, the dense ecosystem of immune cells, signaling molecules and structural cells that surrounds and infiltrates every malignancy.

To test that hypothesis, the investigators assembled a retrospective cohort of 80 patients with non-muscle invasive bladder cancer who had been treated with BCG instillation. From each patient, tumor tissue collected before the start of therapy was available, allowing the researchers to examine the pre-treatment immune context rather than the post-treatment state, which is far more informative for prediction. Using immunohistochemical staining, a laboratory technique that uses antibodies to mark specific cell types on tissue sections so they can be counted under a microscope, the team quantified the densities of key immune cell populations across different tumor compartments, distinguishing between cells located within the tumor epithelium and those in the surrounding stroma, the supportive connective tissue that frames the malignancy.

The analytical pipeline combined classical survival statistics with modern variable-selection methods. The researchers first applied univariate Cox regression, a statistical technique that estimates the association between each candidate marker and the time to recurrence, to identify which immune measurements carried prognostic weight. They then used Lasso analysis, a regression method that shrinks the coefficients of weak predictors toward zero and thereby filters out noise in datasets where the number of variables can easily overwhelm the number of patients. This two-step approach converged on two independent prognostic markers: the total density of CD4-positive T cells across the tumor, and the density of CD68-positive macrophages specifically within the tumor stroma, abbreviated CD68s.

Both markers make biological sense in the context of BCG therapy. CD4-positive T cells are helper lymphocytes that orchestrate adaptive immune responses, coordinating the attack on infected or malignant cells and sustaining immunological memory. BCG instillation is thought to work partly by recruiting and activating these cells within the bladder wall, so a tumor already rich in CD4-positive cells may be primed to respond. CD68-positive macrophages, meanwhile, are phagocytic innate immune cells whose behavior in tumors is famously double-edged: some subsets support anti-tumor inflammation while others suppress immunity and promote tissue remodeling. Their density in the stromal compartment, the corridor through which immune cells migrate into the tumor, appears to encode information about how the tumor microenvironment will handle the inflammatory storm that BCG triggers.

Rather than relying on either marker alone, the team built a combined risk score, a weighted mathematical function of CD4 and CD68s values, and found that this composite measure demonstrated better predictive accuracy and discriminatory power than either marker in isolation. Discrimination, in the language of survival analysis, refers to a model’s ability to correctly rank patients by their risk, separating those who will recur from those who will remain disease-free. The improvement from combining two immune markers of different lineages, one adaptive and one innate, suggests that recurrence after BCG is not governed by a single cell type but by the interplay between the two arms of the immune system within the tumor microenvironment.

The next step was to translate the risk score into something a clinician could actually use at the bedside. The researchers constructed a nomogram, a graphical calculating tool that assigns points to each predictor and sums them into a probability estimate, integrating the immune-based risk score with standard clinicopathological features. When benchmarked against the established EORTC, CUETO and European Association of Urology (EAU) risk stratification models, the new nomogram showed slightly improved predictive performance and, importantly, greater net clinical benefit. Net benefit is a decision-analytic measure that weighs the consequences of true and false predictions, asking not merely whether the model is statistically accurate but whether acting on its predictions would help more patients than it would harm.

The clinical implications of such a tool are substantial. Patients identified before therapy as likely to be BCG-unresponsive could be steered toward alternative strategies earlier, avoiding months of ineffective instillations during which their disease might progress. Conversely, patients predicted to respond well could be spared more aggressive interventions, such as early radical cystectomy, the surgical removal of the bladder, which is sometimes recommended for high-risk disease but carries significant morbidity and a lasting impact on quality of life. Because the required measurements come from immunohistochemical staining of routinely collected biopsy or resection specimens, the approach could in principle be implemented in pathology laboratories without exotic equipment, though the authors’ cohort of 80 patients is modest and the findings will need validation in larger, independent and ideally prospective cohorts before entering clinical guidelines.

The study also contributes to a broader shift in oncology, in which the tumor immune microenvironment has moved from a subject of basic research to a source of actionable biomarkers. Similar immune-contexture scoring systems have transformed prognostication in colorectal cancer, melanoma and other malignancies, and immune checkpoint inhibitors have made the composition of immune infiltrates a central consideration in treatment selection across many tumor types. Applying this lens to BCG therapy is particularly apt, because BCG is, in essence, one of the oldest forms of immunotherapy, and its variable success has long hinted at the importance of individual immune differences. By showing that two simple, pre-treatment immune measurements can sharpen recurrence prediction beyond what tumor stage and grade alone can offer, the work points toward a more personalized approach to a disease that affects millions worldwide.

For now, the message from Guangzhou is one of cautious optimism. The model built by Lu, Zhong and their colleagues does not replace the established clinical risk tools, but it refines them, adding a biological dimension that those tools have always lacked. If larger studies confirm that CD4 and stromal CD68 densities reliably forecast BCG response, urologists may soon order a panel of immune stains alongside the routine pathology workup, and the decision of whether to proceed with BCG, escalate surveillance or consider more radical options could be made with far greater confidence. In a field where treatment failure is discovered only in retrospect, a test that sees it coming could change the trajectory of care for a substantial share of bladder cancer patients.

Subject of Research: An immune microenvironment-based predictive model for recurrence after BCG therapy in non-muscle invasive bladder cancer

Article Title: Development of an immune microenvironment-based model to predict recurrence after BCG therapy in non-muscle invasive bladder cancer

Article References: Lu, J.-L., Zhong, L., Wen, Y.-L., Cai, T.-N., Qin, Z.-K., Tan, L., & Ye, Y.-L. (2026). Development of an immune microenvironment-based model to predict recurrence after BCG therapy in non-muscle invasive bladder cancer. BMC Cancer. https://doi.org/10.1186/s12885-026-17083-y

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17083-y

Keywords: bladder cancer, BCG therapy, tumor immune microenvironment, CD4 T cells, CD68 macrophages, recurrence prediction, nomogram, immunohistochemistry, biomarkers, EORTC, prognostic model, urothelial carcinoma

The study, published in the Journal of Translational Medicine, combined single-cell RNA sequencing of human bladder cancer specimens across disease stages with tissue-level validation and an orthotopic rat model in which bladder tumors were grown in their natural anatomical location. This stage-spanning design was critical. Rather than sampling tumors at a single point in their evolution, the investigators mapped how the cellular composition of the tumor microenvironment changes as disease progresses from earlier stages through T1 and beyond. The approach allowed them to catch, in molecular detail, the precise moment when the tumor begins to remodel its blood supply and reorganize its immune landscape, a transition that their data place squarely at the T1 boundary.

The central discovery concerns a specialized population of blood vessel cells. The researchers found that T1 tumors are characterized by a marked expansion of endothelial cells expressing the chemokine receptor CXCR4, so-called tip endothelial cells that lead the forward advance of growing blood vessels during angiogenesis. These CXCR4-positive tip cells displayed strong angiogenic activity, driving the formation of new vasculature that feeds the expanding tumor. Crucially, however, they showed low expression of adhesion molecules, the molecular tethers that normally allow immune cells traveling in the bloodstream to grab onto vessel walls and squeeze through into surrounding tissue. The result is a vascularly restrictive niche: blood vessels that are metabolically active and proliferative but functionally closed to T-cell traffic, creating a barrier that keeps cytotoxic immune cells out of the tumor bed precisely when the immune system needs access most.

The single-cell data revealed that this vascular barrier does not arise in isolation. Surrounding the CXCR4-positive endothelium, the investigators identified metabolically activated pericytes, the contractile support cells that wrap around blood vessels and regulate their maturation and function. Alongside them, the atlas documented an expansion of macrophages characterized by expression of SPP1, the gene encoding osteopontin, a secreted protein associated with tissue remodeling and immunosuppression. A particularly important subpopulation of these macrophages, marked by expression of MT1X and associated with hypoxic conditions within the tumor, was found to produce vascular endothelial growth factor, or VEGF, the master signaling molecule of angiogenesis. In other words, oxygen-starved regions of the T1 tumor recruit and reprogram macrophages, which in turn secrete VEGF to sustain the very CXCR4-positive tip endothelial cells that wall off the tumor from immune attack. The vascular niche and the immune exclusion it produces are thus two faces of a single, self-reinforcing circuit.

At the same time that this restrictive vasculature was emerging, the atlas captured the beginnings of an organized adaptive immune response within T1 tumors. The researchers observed the appearance of CXCL13-positive T cells, a subset of T helper cells known to orchestrate the recruitment and organization of B cells, together with B-cell gene expression programs characteristic of tertiary lymphoid structures, or TLSs. These are ectopic, lymph-node-like aggregates that form within tissues at sites of chronic inflammation and are widely regarded as favorable prognostic features in many cancers, because they provide local sites where anti-tumor immune responses can be initiated and sustained. Their emergence at the T1 stage suggested that the immune system is attempting to mount a structured response against the tumor even as the vasculature works to exclude it, setting up a competition between two opposing biological programs within the same tissue.

When the investigators compared tumors from patients who responded to BCG therapy with those from patients who did not, the outcome of that competition proved decisive. Mature tertiary lymphoid structures were preferentially enriched in BCG responders, indicating that the ability to build fully organized immune aggregates within the bladder wall correlates with successful response to the vaccine. Conversely, CXCR4-positive tip endothelial cells were enriched in non-responders, consistent with the idea that a vascularly restrictive niche prevents the intravesically administered BCG from generating an effective anti-tumor immune infiltrate. The two cell populations thus function as opposing biomarkers: one signaling an immune microenvironment capable of supporting BCG-induced tumor killing, the other signaling a physical and immunological barrier that the therapy cannot penetrate.

The mechanistic implications of these findings were tested directly in the orthotopic rat model. Because the MT1X-positive, hypoxia-associated macrophages were identified as the source of VEGF driving the CXCR4-positive endothelial program, the researchers reasoned that pharmacologically blocking VEGF-family signaling might dismantle the vascular barrier and restore immune access to the tumor. They treated tumor-bearing animals with sunitinib, a multi-targeted tyrosine kinase inhibitor that blocks both VEGF receptors and PDGF receptors, thereby targeting both the endothelial compartment and the pericyte support cells that stabilize tumor vessels. The results supported the hypothesis: sunitinib enhanced the efficacy of BCG therapy in vivo, providing proof of principle that the vascular-immune niche identified in the human atlas is not merely a correlate of treatment failure but a functional, targetable determinant of response.

The clinical significance of this work is considerable. BCG has been the backbone of treatment for non-muscle-invasive bladder cancer since the late twentieth century, yet a substantial fraction of patients either fail to respond initially or lose response over time, and the only definitive option for BCG-unresponsive disease has historically been radical cystectomy, a major surgical procedure with significant morbidity. A molecular signature capable of stratifying patients at the T1 stage, before months of BCG courses have been completed and precious time has been lost, could allow clinicians to identify likely non-responders early and direct them toward alternative strategies, whether that means combining BCG with vascular-targeting agents, enrolling them in trials of novel intravesical or systemic immunotherapies, or considering earlier surgical intervention. The identification of CXCR4-positive tip endothelial cells as enriched in non-responders and mature TLSs as enriched in responders offers exactly such a stratification framework, grounded in specific, measurable cellular features of the tumor microenvironment.

Beyond its immediate translational promise, the study contributes a conceptual advance to tumor immunology. It reframes the transition from non-invasive to T1 bladder cancer not simply as a matter of deeper tumor penetration but as a coordinated remodeling event in which angiogenic endothelium, pericytes, hypoxic macrophages, and emerging lymphoid structures are locked into a dynamic balance that determines whether immunotherapy can succeed. The vascular-immune crosstalk documented in this atlas, in which VEGF from hypoxia-associated macrophages builds a vessel wall that excludes T cells while CXCL13-positive T cells labor to assemble tertiary lymphoid structures on the other side, provides a mechanistic template that may be relevant well beyond the bladder. The authors note that their atlas defines a T1-stage vascular-immunosuppressive niche linking vascular remodeling, immune accessibility, TLS maturation, and BCG responsiveness, and the demonstration that sunitinib can potentiate BCG in vivo suggests a concrete path toward overcoming BCG resistance. If validated in prospective human studies, the strategy of priming the tumor vasculature before or during BCG instillation could transform the management of one of the most common and treatment-resistant forms of bladder cancer, turning a vascular barrier that has silently sabotaged immunotherapy into a therapeutic target in its own right.

Subject of Research: Single-cell mapping of the T1-stage vascular-immune microenvironment and its role in BCG therapy response in bladder cancer

Article Title: Stage-spanning single-cell mapping reveals a T1 vascular–immune barrier linked to BCG response in bladder cancer

Article References: Song, S., Shao, Y., Wei, Y., Li, P., Yang, Z., Li, S., Zhang, H., Lu, Y., Fang, C., Wang, C., Liu, T., Yang, B., An, H., Liu, L., Tian, J., Hu, H., & Shang, Z. (2026). Stage-spanning single-cell mapping reveals a T1 vascular–immune barrier linked to BCG response in bladder cancer. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09023-y

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09023-y

Keywords: bladder cancer, BCG therapy, single-cell RNA sequencing, tumor microenvironment, angiogenesis, CXCR4, tip endothelial cells, tertiary lymphoid structures, VEGF, sunitinib, macrophages, immunotherapy resistance